Captor Therapeutics SA(DE:60Q)
€11.62-0.04 (-0.34%)
DE:60Q
Captor Therapeutics SA stock drug pipeline
€11.62
At close:-0.04 (-0.34%)
Captor Therapeutics SA (60Q) Drug Pipeline
1 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Everolimus, Ct-01 | Hepatocellular Carcinoma (Hcc) | Phase I | Not Yet Recruiting | Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma | Apr 29, 2025 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Everolimus, Ct-01 | Phase I | Hepatocellular Carcinoma (Hcc) | Not Yet Recruiting | Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma | Apr 29, 2025 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Captor Therapeutics SA (DE:60Q) have in its pipeline
Captor Therapeutics SA DE:60Q is currently developing the following drugs: Everolimus, Ct-01. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
